Pfizer, Aventis Still See Wiggle Room On FDA-Mandated Switches
This article was originally published in The Tan Sheet
Executive Summary
FDA likely will face a legal challenge regardless of whether the agency decides to implement mandated Rx-to-OTC switches or chooses a more indirect policy yielding similar results, according to comments made by Aventis and Pfizer executives
You may also be interested in...
FDA’s Crawford Backs Away From Forced Antihistamine Switch Controversy
FDA says it would like to "stimulate" Rx-to-OTC switches where appropriate, but not "force" the policy on drug makers
FDA’s Crawford Backs Away From Forced Antihistamine Switch Controversy
FDA says it would like to "stimulate" Rx-to-OTC switches where appropriate, but not "force" the policy on drug makers
FDA’s Crawford Backs Away From Forced Antihistamine Switch Controversy
FDA says it would like to "stimulate" Rx-to-OTC switches where appropriate, but not "force" the policy on drug makers